The FOXK2 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Raji B lymphocyte line. The introduction of CRISPR/Cas9-mediated gene disruption creates a heterogeneous pool of FOXK2-deficient cells that enables population-level functional studies of FOXK2 loss-of-function without clonal bias. This model supports direct comparisons with wild-type Raji cells in a variety of assays to interrogate FOXK2??s roles in B-cell lymphoma, signal transduction, and gene regulation.
The Raji cell line originates from an EBV-positive Burkitt??s lymphoma and displays a lymphoblastoid phenotype, including surface immunoglobulin M expression and suspension growth. These B lymphocytes provide a well-characterized model of germinal center-derived lymphoma, retaining key oncogenic features that facilitate investigation of FOXK2 within the context of EBV-driven and PI3K/AKT-mediated signaling networks.
FOXK2 is a forkhead transcription factor that integrates signals from PI3K/AKT and Wnt pathways to regulate cell cycle arrest and apoptosis. It transcriptionally activates target genes such as CDKN1A (p21), BCL2L11 (Bim), and FASLG, which inhibit proliferation and promote cell death. AKT phosphorylation of FOXK2 at Ser423 promotes 14-3-3 binding, leading to cytoplasmic retention and degradation, thereby suppressing its tumor-suppressive function. This regulation is modulated by GSK3 and involves interactions with ??-catenin, FOXO, and SMAD proteins. Downstream, FOXK2 also controls cyclin D1 and metabolic enzyme G6PC, positioning it as a key coordinator of proliferation and survival in B cells.
In Raji lymphoma cells, FOXK2??s growth-inhibitory function is often attenuated by constitutive AKT signaling, which drives its cytoplasmic sequestration. Disruption of FOXK2 in this polyclonal knockout model removes residual tumor-suppressive activity, enabling direct assessment of the consequences of complete FOXK2 loss on lymphoma proliferation, survival, and therapy response. This system is particularly useful for dissecting the interplay between AKT-mediated FOXK2 regulation and EBV oncoproteins, and for testing whether PI3K/AKT inhibitors exert their effects in part through reactivation of FOXK2.
Researchers can employ these cells in a wide array of assays, including western blotting for FOXK2, p-AKT, and p21; RT-qPCR and ChIP-qPCR for analyzing FOXK2 target gene transcription; immunofluorescence to assess FOXK2 localization; and flow cytometry for apoptosis and cell cycle profiling. Co-immunoprecipitation studies confirm disrupted 14-3-3 interactions, while drug sensitivity testing with PI3K/AKT inhibitors evaluates therapeutic relevance. This polyclonal knockout population offers a versatile tool for studying FOXK2 in lymphoma biology and drug discovery. For further information or to discuss custom applications, please contact Ascent Research.
